Jump to content

Steve-o

Members
  • Posts

    29
  • Joined

  • Last visited

Recent Profile Visitors

231 profile views

Steve-o's Achievements

2

Reputation

  1. https://patentimages.storage.googleapis.com/68/80/73/6a17a66e9ec8c5/US11107588.pdf System and methods for anonymously selecting subjects for treatment against an infectious disease caused by a patho gen . The system comprises a plurality of electronic devices comprising instructions to generate an ID and , when in proximity of another such electronic device , one or both electronic devices transmit / receive the ID to / from the other electronic device . Then , a score is generated based on a plurality of such received IDs . Additionally , based on infor mation received from a server , relevant treatment instruc tions are displayed to the subjects based on the received information and the score . The server comprises instructions for sending to the plurality of electronic devices the infor mation to be displayed with the relevant treatment instruc tions , additionally the server and / or the electronic devices comprise instructions to generate a prediction of likelihood of a subject transmitting the pathogen , based on the score of the subject .
  2. LONDON, March 18 (Reuters) - Late last year, a semi-retired British scientist co-authored a petition to Europe's medicines regulator. The petitioners made a bold demand: Halt COVID-19 vaccine clinical trials. Even bolder was their argument for doing so: They speculated, without providing evidence, that the vaccines could cause infertility in women. The document appeared on a German website on Dec.1. Scientists denounced the theory. Regulators weren't swayed, either: Weeks later, the European Medicines Agency approved the European Union's first COVID-19 shot, co-developed by Pfizer Inc. But damage was already done. Social media quickly spread exaggerated claims that COVID-19 jabs cause female infertility. Within weeks, doctors and nurses in Britain began reporting that concerned women were asking them whether it was true, according to the Royal College of Obstetricians & Gynaecologists. In January, a survey by the Kaiser Family Foundation (KFF), a non-profit organization, found that 13% of unvaccinated people in the United States had heard that "COVID-19 vaccines have been shown to cause infertility." What gave the debunked claim credibility was that one of the petition's co-authors, Michael Yeadon, wasn't just any scientist. The 60-year-old is a former vice president of Pfizer, where he spent 16 years as an allergy and respiratory researcher. He later co-founded a biotech firm that the Swiss drugmaker Novartis purchased for at least $325 million. In recent months, Yeadon (pronounced Yee-don) has emerged as an unlikely hero of the so-called anti-vaxxers, whose adherents question the safety of many vaccines, including for the coronavirus. The anti-vaxxer movement has amplified Yeadon's skeptical views about COVID-19 vaccines and tests, government-mandated lockdowns and the arc of the pandemic. Yeadon has said he personally doesn't oppose the use of all vaccines. But many health experts and government officials worry that opinions like his fuel vaccine hesitancy – a reluctance or refusal to be vaccinated – that could prolong the pandemic. COVID-19 has already killed more than 2.6 million people worldwide. "These claims are false, dangerous and deeply irresponsible," said a spokesman for Britain's Department of Health & Social Care, when asked about Yeadon's views. "COVID-19 vaccines are the best way to protect people from coronavirus and will save thousands of lives." Recent reports of blood clots and abnormal bleeding in a small number of recipients of AstraZeneca's COVID-19 vaccine have cast doubt on that shot's safety, leading several European countries to suspend its use. The developments are likely to fuel vaccine hesitancy further, although there is no evidence of a causative link between the AstraZeneca product and the affected patients' conditions. Yeadon didn't respond to requests for comment for this article. In reporting this story, Reuters reviewed thousands of his tweets over the past two years, along with other writings and statements. It also interviewed five people who know him, including four of his former colleagues at Pfizer. A Pfizer spokesman declined to comment on Yeadon and his stint with the company, beyond emphasizing that there is no evidence that its vaccine, which it developed with its German partner BioNTech, causes infertility in women. References to Yeadon's petition appear on the website of a group founded by influential vaccine skeptic Robert F. Kennedy Jr., scion of the American political dynasty, who recently was banned on Instagram because of his COVID-19 vaccine posts. Syndicated writer and vaccine skeptic Michelle Malkin reported Yeadon's concern about fertility in a column last month under the headline, "Pregnant Women: Beware of COVID Shots." And a blog with an alarmist headline – "Head of Pfizer Research: Covid vaccine is female sterilization" – was shared thousands of times on Facebook. The visage and views of Yeadon, widely identified as an "Ex-VP of Pfizer," can be seen on social media in languages including German, Portuguese, Danish and Czech. A Facebook post carries a video from November in which Yeadon claimed that the pandemic "fundamentally… is over." The post has been viewed more than a million times. In October, Yeadon wrote a column for the United Kingdom's Daily Mail newspaper that also appeared on MailOnline, one of the world's most-visited news websites. It declared that deaths caused by COVID-19, which then totaled about 45,000 in Britain, will soon "fizzle out" and Britons "should immediately be allowed to resume normal life." Since then, the disease has killed about another 80,000 people in the UK. Yeadon isn't the only respected scientist to have challenged the scientific consensus on COVID-19 and expressed controversial views. Michael Levitt, a winner of the Nobel Prize for chemistry, told the Stanford Daily last summer that he expected the pandemic would end in the United States in 2020 and kill no more than 175,000 Americans – a third of the current total – and "when we come to look back, we're going to say that wasn't such a terrible disease." And Luc Montagnier, another Nobel Prize winner, said last year that he believed the coronavirus was created in a Chinese lab. Many experts doubt that, but so far there is no way to prove or disprove it. Levitt told Reuters that his projections about the pandemic in the United States were wrong, but he still believes COVID-19 eventually won't be seen as "a terrible disease" and that lockdowns "caused a great deal of collateral damage and may not have been needed." Montagnier didn't respond to a request for comment. What gives Yeadon particular credibility is the fact that he worked at Pfizer, says Imran Ahmed, chief executive of the Center for Countering Digital Hate, an organization that combats online misinformation. "Yeadon's background gives his dangerous and harmful messages false credibility." In a debate last fall in Britain's House of Commons about the government's response to the pandemic, parliamentarian Richard Drax called Yeadon an "eminent" scientist, and cited his view "that the virus is both manageable and nearing its end." Drax didn't respond to a request for comment. More recently, David Kurten, a member of the London Assembly – an elected body – tweeted there is a "real danger" that COVID-19 vaccines could leave women infertile. "The 'cure' must not be worse than the 'disease'," Kurten wrote. He, too, didn't respond to a request for comment. Why Yeadon transformed from mainstream scientist to COVID-19 vaccine skeptic remains a mystery. Thousands of his tweets stretching back to the start of the pandemic document a dramatic shift in his views – early on, he supported a vaccine strategy. But they offer few clues to explain his radical turnabout. Some former colleagues at Pfizer say they no longer recognize the Mike Yeadon they once knew. They described him as a knowledgeable and intelligent man who always insisted on seeing evidence and generally avoided publicity. One of those ex-colleagues is Sterghios A. Moschos, who holds degrees in molecular biology and pharmaceutics. In December, Yeadon posted on Twitter a spoof sign that said, "DITCH THE MASK." Moschos tweeted back: "Mike what hell ?! Are you out to actively kill people? You do realize that if you are wrong, your suggestions will result in deaths ??" "IT'LL ALL FADE AWAY" Yeadon joined Twitter in October 2018 and soon became a prolific user of the platform. The thousands of his tweets reviewed by Reuters were provided by archive.org, which stores web pages, and FollowersAnalysis, a social media analytics company. When the coronavirus pandemic reached the UK in March 2020, Yeadon initially expressed support for developing a vaccine. He tweeted: "Covid 19 is not going away. Until we have a vaccine or herd immunity" – natural resistance resulting from prior exposure to the virus – "all that can be done is to slow its spread." A week later he tweeted: "A vaccine might be along towards the end of 2021, if we're really lucky." When a fellow Twitter user said vaccines "harm many, many people," Yeadon replied: "Ok, please refuse it, but do not impede its flow to neutrals or those keen to get it, thanks." After Mathai Mammen, the global head of research & development for Janssen, the pharmaceutical division of Johnson & Johnson, posted on LinkedIn last summer that his company had started clinical trials of a vaccine, Yeadon responded: "Lovely to see this milestone, Mathai!" Mammen didn't respond to a request for comment. But as early as April, Yeadon had begun voicing unorthodox views. While Britain was still in its first lockdown last spring, he declared: "there is nothing especially virulent or frightening about covid 19 … it'll all fade away … Just a common & garden virus, to which the world overreacted." And he predicted in a subsequent tweet that it was "unlikely" the death toll in the UK would reach 40,000. By September 2020, Yeadon's statements were attracting attention beyond Twitter. At the time, a movement had emerged in Britain against lockdowns and other restrictions meant to curb the disease. He co-authored a lengthy article on a website called Lockdown Sceptics. It declared that the "pandemic as an event in the UK is essentially complete." And, "There is no biological principle that leads us to expect a second wave." Britain soon entered a much more deadly second wave. On Oct. 16, he wrote another lengthy article for the same website: "There is absolutely no need for vaccines to extinguish the pandemic. I've never heard such nonsense talked about vaccines. You do not vaccinate people who aren't at risk from a disease." In November, Yeadon appeared in a 32-minute video for the anti-lockdown group, Unlocked, sitting in a shed with a motorbike behind him. A shorter version appeared on Facebook titled, "The pandemic is over." Yeadon called for an end to mass testing and claimed that 30% of the population was already immune to COVID-19 even before the pandemic started. By the time of the recording, he said, there was little scope for the virus to spread further in the UK because most people had already been infected or were immune. Those views ran counter to the findings of the World Health Organization. In December – nine months after declaring the COVID-19 outbreak a pandemic – the agency said testing suggested that less than 10% of the world's population had shown evidence of infection. Yeadon's petition to the European Medicines Agency to halt vaccine trials followed on Dec. 1. The agency didn't respond to requests for comment for this article. It's impossible to measure the impact of Yeadon's claim that COVID-19 vaccines could cause female infertility. Anecdotally, though, many women have bought into it. Bonnie Jacobson, a waitress in Brooklyn, New York, can't recall where she first heard about the fertility issue. But she told Reuters that it has made her hesitant to take a vaccine, as she'd like to have children "sooner than later." "That's my main concern," she said. "Let more research come out." After recently declining to get vaccinated, she said, the tavern where she worked fired her. Jacobson's employer didn't respond to a request for comment. A GOOD SCIENTIST According to Yeadon's LinkedIn profile, he joined Pfizer in 1995; the company had a large operation then in Sandwich in southern England. He rose to become a vice president and head of allergy and respiratory research. Many former colleagues say they are baffled by his transformation. Mark Treherne, chairman of Talisman Therapeutics in Cambridge, England, said he overlapped with Yeadon at Pfizer for about two years and sometimes had coffee with him. "He always seemed knowledgeable, intelligible, a good scientist. We were both trained as pharmacologists … so we had something in common." "I obviously disagree with Mike and his recent views," he said. Treherne's company is researching brain inflammation, which he said could be triggered by coronaviruses. "This does not sound like the guy I knew 20 years ago." Moschos, the ex-colleague who took issue with one of Yeadon's tweets, said he considered him a mentor when they worked together at the drugmaker from 2008 to 2011. More recently, Moschos has been researching whether it's possible to test for COVID-19 with breath samples. He said Yeadon's views are "a huge disappointment." He recounted hearing Yeadon in a radio interview last year. "There was a tone in his voice that was nothing like I ever remembered of Mike," Moschos said. "It was very angry, very bitter." John LaMattina, a former president of Pfizer Global Research and Development, also knew Yeadon. "His group was very successful and discovered a number of compounds that entered early clinical development," LaMattina told Reuters in an email. He said Yeadon and his team were let go by Pfizer, however, when the company made the strategic decision to exit the therapeutic area they were researching. LaMattina said he had lost touch with Yeadon in recent years. Shown links to Yeadon's video declaring the pandemic over and a copy of his petition to halt COVID-19 clinical trials, LaMattina replied: "This is all news to me and a bit of a shock. This seems out of character for the person I knew." "CHUTZPAH" After losing his job at Pfizer in 2011, Yeadon set up a biotech company called Ziarco with three Pfizer colleagues. They wanted to continue researching promising therapies that targeted allergies and inflammatory diseases, ideas Pfizer had been developing but were at risk of being abandoned. Yeadon served as Ziarco's chief executive. "I simply showed chutzpah and asked the senior-most people up the research line" at Pfizer to support the venture, Yeadon later recalled in an interview with Forbes. "And they said, 'OK, assuming you raise private capital.'" In 2012, Ziarco announced it had initially secured funding from several investors, including Pfizer's venture capital arm. Other investors later joined, including an Amgen Inc corporate venture capital fund. Amgen didn't respond to a request for comment. "The intensity of effort took me away almost completely from my family and other interests for almost five years and you get only one life," Yeadon told Forbes. On Twitter, Yeadon said he is married and has two adult daughters, and described a tough childhood – he said his mother committed suicide when he was 18 months old and his father, a doctor, abandoned him when he was 16. He said he was saved by a local social worker and adopted by a Jewish family whose "open handed love turned my life around." While at Ziarco, Yeadon also worked as a consultant for several years at two Boston-area biotech companies, Apellis Pharmaceuticals and Pulmatrix Inc. Both firms said he no longer advises them. A spokeswoman for Apellis said, "His views do not reflect those of Apellis." She didn't elaborate. The hard work at Ziarco paid off. In January 2017, Novartis acquired the company for an upfront payment of $325 million, with the promise of $95 million more if certain milestones were met, according to Novartis' 2017 annual report. Novartis was betting on the promise of a Ziarco drug, known as ZPL389, that had the potential to be a "first-in-class oral treatment for moderate-to-severe eczema," a common and sometimes debilitating rash. Reuters wasn't able to determine how much money Yeadon made from Novartis' purchase of Ziarco. But in January 2020 he tweeted: "Oddly enough, I made millions from founding & growing a biotech company, creating many highly paid jobs, using my PhD & persuasion around the world." Last July, Novartis disclosed it had discontinued the ZPL389 clinical development program and had taken a $485 million write down. A Novartis spokesman said the company decided to terminate the program after disappointing efficacy data in an early-stage clinical trial. "I'LL SOON BE GONE" Earlier this year, a group of Yeadon's former Pfizer colleagues expressed their concern in a private letter, according to a draft reviewed by Reuters. "We have become acutely aware of your views on COVID-19 over the last few months … the single mindedness, lack of scientific rigour and one sided interpretation of often poor quality data is far removed from the Mike Yeadon we so respected and enjoyed working with." Noting his "vast following on social media" and that his claim about infertility "has spread globally," the group wrote, "We are very worried that you are putting people's health at risk." Reuters couldn't determine whether Yeadon received the letter. On Feb. 3, Yeadon's Twitter account had a message for his 91,000 followers: "A tweet recently appeared under my ID, which was horribly offensive. As a result my account was locked. I of course deleted it. I want you to know of course that I didn't write it." A Twitter spokesman declined to comment. Yeadon didn't make clear what tweet he was referring to. But shortly after, several Twitter users and a blog called Zelo Street posted screenshots of numerous offensive anti-Muslim tweets from Yeadon's account from about a year ago. Many were captured at the time by archive.org. The next day, on Feb. 4, Yeadon cryptically mentioned in a tweet, "I'll soon be gone." Two days later, he was off Twitter. His followers were greeted with this message: "This account doesn't exist." His LinkedIn profile also soon changed, now stating that he is "Fully retired." Clare Craig, a British pathologist, compared Yeadon's treatment on Twitter – where some users derided his views as nonsense and dangerous – to medieval societies burning heretics at the stake. "There is no other way to see it than the burning of the witches," said Craig, who has criticized lockdowns and COVID-19 tests. "Science is always a series of questions and the testing of those questions and when we are not allowed to ask those questions, then science is lost." She said she spoke to Yeadon after he closed his Twitter account. "He will have a think about how he will contribute in the future," she said. ((Reporting by Steve Stecklow and Andrew MacAskill; Edited by Janet McBride))
  3. I`m trying without violent, all demonstrations tend to achieve is ending up in court or jail, disobedience ends up with a big fine that you have to pay or end up in court or jail!!!!! So really nothing works, what do you think?
  4. Sign this petition https://petition.parliament.uk/petitions/602282 Do not under any circumstances make vaccination against Covid-19 a requirement for the public. To coerce in the form of fines or otherwise, as is being proposed in Austria, would be a grotesque violation of bodily autonomy.
  5. By the authority vested in me as President by the Constitution and the laws of the United States of America, including section 301 of title 3, United States Code, it is hereby ordered as follows: Section 1. Findings. (a) Influenza viruses are constantly changing as they circulate globally in humans and animals. Relatively minor changes in these viruses cause annual seasonal influenza outbreaks, which result in millions of illnesses, hundreds of thousands of hospitalizations, and tens of thousands of deaths each year in the United States. Periodically, new influenza A viruses emerge from animals, including birds and pigs, that can spread efficiently and have sustained transmission among humans. This situation is called an influenza pandemic (pandemic). Unlike seasonal influenza, a pandemic has the potential to spread rapidly around the globe, infect higher numbers of people, and cause high rates of illness and death in populations that lack prior immunity. While it is not possible to predict when or how frequently a pandemic may occur, there have been 4 pandemics in the last 100 years. The most devastating pandemic occurred in 1918-1919 and is estimated to have killed more than 50 million people worldwide, including 675,000 Americans. (b) Vaccination is the most effective defense against influenza. Despite recommendations by the Centers for Disease Control and Prevention (CDC) that nearly every American should receive the influenza vaccine annually, however, seasonal influenza vaccination levels in the United States have currently reached only about 45 percent of CDC goals. (c) All influenza vaccines presently in use have been developed for circulating or anticipated influenza viruses. These vaccines must be reformulated for each influenza season as well as in the event of a pandemic. Additional research is needed to develop influenza vaccines that provide more effective and longer-lasting protection against many or all influenza viruses. (d) The current domestic enterprise for manufacturing influenza vaccines has critical shortcomings. Most influenza vaccines are made in chicken eggs, using a 70-year-old process that requires months-long production timelines, limiting their utility for pandemic control; rely on a potentially vulnerable supply chain of eggs; require the use of vaccine viruses adapted for growth in eggs, which could introduce mutations of the influenza vaccine virus that may render the final product less effective; and are unsuitable for efficient and scalable continuous manufacturing platforms. (e) The seasonal influenza vaccine market rewards manufacturers that deliver vaccines in time for the influenza season, without consideration of the speed or scale of these manufacturers' production processes. This approach is insufficient to meet the response needs in the event of a pandemic, which can emerge rapidly and with little warning. Because the market does not sufficiently reward speed, and because a pandemic has the potential to overwhelm or compromise essential government functions, including defense and homeland security, the Government must take action to promote faster and more scalable manufacturing platforms. Sec. 2. Policy. It is the policy of the United States to modernize the domestic influenza vaccine enterprise to be highly responsive, flexible, scalable, and more effective at preventing the spread of influenza viruses. This is a public Start Printed Page 49936health and national security priority, as influenza has the potential to significantly harm the United States and our interests, including through large-scale illness and death, disruption to military operations, and damage to the economy. This order directs actions to reduce the United States' reliance on egg-based influenza vaccine production; to expand domestic capacity of alternative methods that allow more agile and rapid responses to emerging influenza viruses; to advance the development of new, broadly protective vaccine candidates that provide more effective and longer lasting immunities; and to support the promotion of increased influenza vaccine immunization across recommended populations. Sec. 3. National Influenza Vaccine Task Force. (a) There is hereby established a National Influenza Vaccine Task Force (Task Force). The Task Force shall identify actions to achieve the objectives identified in section 2 of this order and monitor and report on the implementation and results of those actions. The Task Force shall be co-chaired by the Secretary of Defense and the Secretary of Health and Human Services, or their designees. (b) In addition to the Co-Chairs, the Task Force shall consist of a senior official from the following executive branch departments, agencies, and offices: (i) the Department of Defense (DOD); (ii) the Department of Justice; (iii) the Department of Agriculture; (iv) the Department of Veterans Affairs (VA); (v) the Department of Homeland Security; (vi) the United States Food and Drug Administration; (vii) the Centers for Disease Control and Prevention; (viii) the National Institutes of Health (NIH); (ix) the Centers for Medicare and Medicaid Services (CMS); and (x) the Biomedical Advanced Research and Development Authority (BARDA). (c) The Co-Chairs may jointly invite additional Federal Government representatives, with the consent of the applicable executive department, agency, or office head, to attend meetings of the Task Force or to become members of the Task Force, as appropriate. (d) The staffs of the Department of State, the Office of Management and Budget (OMB), the National Security Council, the Council of Economic Advisers, the Domestic Policy Council, the National Economic Council, and the Office of Science and Technology Policy (OSTP) may attend and participate in any Task Force meetings or discussions. (e) The Task Force may consult with State, local, tribal, and territorial government officials and private sector representatives, as appropriate and consistent with applicable law. (f) Within 120 days of the date of this order, the Task Force shall submit a report to the President, through the Assistant to the President for National Security Affairs, the Assistant to the President for Domestic Policy, the Director of the Office of Management and Budget, and the Director of the Office of Science and Technology Policy. The report shall include: (i) a 5-year national plan (Plan) to promote the use of more agile and scalable vaccine manufacturing technologies and to accelerate development of vaccines that protect against many or all influenza viruses; (ii) recommendations for encouraging non-profit, academic, and private-sector influenza vaccine innovation; and (iii) recommendations for increasing influenza vaccination among the populations recommended by the CDC and for improving public understanding of influenza risk and informed influenza vaccine decision-making.Start Printed Page 49937 (g) Not later than June 1 of each of the 5 years following submission of the report described in subsection (f) of this section, the Task Force shall submit an update on implementation of the Plan and, as appropriate, new recommendations for achieving the policy objectives set forth in section 2 of this order. Sec. 4. Agency Implementation. The heads of executive departments and agencies shall also implement the policy objectives defined in section 2 of this order, consistent with existing authorities and appropriations, as follows: (a) The Secretary of HHS shall: (i) through the Assistant Secretary for Preparedness and Response and BARDA: (A) estimate the cost of expanding and diversifying domestic vaccine-manufacturing capacity to use innovative, faster, and more scalable technologies, including cell-based and recombinant vaccine manufacturing, through cost-sharing agreements with the private sector, which shall include an agreed-upon pricing strategy during a pandemic; (B) estimate the cost of expanding domestic production capacity of adjuvants in order to combine such adjuvants with both seasonal and pandemic influenza vaccines; (C) estimate the cost of expanding domestic fill-and-finish capacity to rapidly fulfill antigen and adjuvant needs for pandemic response; (D) estimate the cost of developing, evaluating, and implementing delivery systems to augment limited supplies of needles and syringes and to enable the rapid and large-scale administration of pandemic influenza vaccines; (E) evaluate incentives for the development and production of vaccines by private manufacturers and public-private partnerships, including, in emergency situations, the transfer of technology to public-private partnerships—such as the HHS Centers for Innovation and Advanced Development and Manufacturing or other domestic manufacturing facilities—in advance of a pandemic, in order to be able to ensure adequate domestic pandemic manufacturing capacity and capability; (F) support, in coordination with the DOD, NIH, and VA, a suite of clinical studies featuring different adjuvants to support development of improved vaccines and further expand vaccine supply by reducing the dose of antigen required; and (G) update, in coordination with other relevant public health agencies, the research agenda to dramatically improve the effectiveness, efficiency, and reliability of influenza vaccine production; (ii) through the Director of NIH, provide to the Task Force estimated timelines for implementing NIH's strategic plan and research agenda for developing influenza vaccines that can protect individuals over many years against multiple types of influenza viruses; (iii) through the Commissioner of Food and Drugs: (A) further implement vaccine production process improvements to reduce the time required for vaccine production (e.g., through the use of novel technologies for vaccine seed virus development and through implementation of improved potency and sterility assays); (B) develop, in conjunction with the CDC, proposed alternatives for the timing of vaccine virus selection to account for potentially shorter timeframes associated with non-egg based manufacturing and to facilitate vaccines optimally matched to the circulating strains; (C) further support the conduct, in collaboration with the DOD, BARDA, and CDC, of applied scientific research regarding developing cell lines and expression systems that markedly increase the yield of cell-based and recombinant influenza vaccine manufacturing processes; andStart Printed Page 49938 (D) assess, in coordination with BARDA and relevant vaccine manufacturers, the use and potential effects of using advanced manufacturing platforms for influenza vaccines; (iv) through the Director of the CDC: (A) expand vaccine effectiveness studies to more rapidly evaluate the effectiveness of cell-based and recombinant influenza vaccines relative to egg-based vaccines; (B) explore options to expand the production capacity of cell-based vaccine candidates used by industry; (C) develop a plan to expand domestic capacity for whole genome characterization of influenza viruses; (D) increase influenza vaccine use through enhanced communication and by removing barriers to vaccination; and (E) enhance communication to healthcare providers about the performance of influenza vaccines, in order to assist them in promoting the most effective vaccines for their patient populations; and (v) through the Administrator of CMS, examine the current legal, regulatory, and policy framework surrounding payment for influenza vaccines and assess adoption of domestically manufactured vaccines that have positive attributes for pandemic response (such as scalability and speed of manufacturing). (b) The Secretary of Defense shall: (i) provide OMB with a cost estimate for transitioning DOD's annual procurement of influenza vaccines to vaccines manufactured both domestically and through faster, more scalable, and innovative technologies; (ii) direct, in coordination with the VA, CDC, and other components of HHS, the conduct of epidemiological studies of vaccine effectiveness to improve knowledge of the clinical effect of the currently licensed influenza vaccines; (iii) use DOD's network of clinical research sites to evaluate the effectiveness of licensed influenza vaccines, including methods of boosting their effectiveness; (iv) identify opportunities to use DOD's vaccine research and development enterprise, in collaboration with HHS, to include both early discovery and design of influenza vaccines as well as later-stage evaluation of candidate influenza vaccines; (v) investigate, in collaboration with HHS, alternative correlates of immune protection that could facilitate development of next-generation influenza vaccines; (vi) direct the conduct of a study to assess the feasibility of using DOD's advanced manufacturing facility for manufacturing cell-based or recombinant influenza vaccines during a pandemic; and (vii) accelerate, in collaboration with HHS, research regarding rapidly scalable prophylactic influenza antibody approaches to complement a universal vaccine initiative and address gaps in current vaccine coverage. (c) The Secretary of VA shall provide OMB with a cost estimate for transitioning its annual procurement of influenza vaccines to vaccines manufactured both domestically and with faster, more scalable, and innovative technologies. Sec. 5. Termination. The Task Force shall terminate upon direction from the President or, with the approval of the President, upon direction from the Task Force Co-Chairs. Sec. 6. General Provisions. (a) Nothing in this order shall be construed to impair or otherwise affect: (i) the authority granted by law to an executive department or agency, or the head thereof; orStart Printed Page 49939 (ii) the functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals. (b) This order shall be implemented consistent with applicable law and subject to the availability of appropriations. (c) This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.   THE WHITE HOUSE, September 19, 2019. Filed 9-23-19; 8:45 am] [FR Doc. 2019-20804 Billing code 3295-F9-P
  6. “What this research has shown is that markers associated with increasing the risk of heart attack and probably even progression of underlying heart disease in people who have already got some heart disease. There’s been a significantly increased risk from 11% at five years, the risk of heart attack, to 25%.” DR ASEEM MALHOTRA, 25 NOVEMBER 2021. A clip of health campaigner and cardiologist Dr Aseem Malhotra on GB News talking about claims linking the Covid-19 vaccines to heart attacks has gone viral on Twitter and been viewed at least one million times. He did say the findings need to be replicated to confirm whether or not they are true, but what Dr Malhotra did not mention is that the journal which published an abstract of the research has issued an “expression of concern” about it, noting that it contains “potential errors” and “may not be reliable”. What the research claims The research claims to have measured various biomarkers (biological characteristics like blood pressure) before and after patients received their second mRNA Covid-19 vaccine dose (such as the Pfizer or Moderna vaccines). It uses these biomarkers to calculate a “PULS score”, pre and post-vaccination, which it claims predicts the five-year risk of developing new acute coronary syndrome (ACS). ACS includes a range of conditions associated with reduced blood flow to the heart, including heart attacks. The research claims that results from 566 patients showed the risk of developing ACS within five years, as measured by the PULS score, increased from 11% before vaccination to 25% after vaccination. It was presented at a meeting of the American Heart Association (AHA) in the form of a poster (a format used by academics to present summary findings of research at conferences). Only the abstract has been published in an open-access format, though screenshots from the poster presentation are circulating on Twitter. Issues The “expression of concern”, issued by the AHA’s journal Circulation, raises a number of issues with the research. One issue is that “there are no statistical analyses for significance provided”, meaning that it is not clear if the results are due to chance or some other factor. The research claims a number of biomarkers indicating heart disease risk were elevated after vaccination, but some of these fall within the margin of error. Of the three biomarkers mentioned in the abstract, only one increased by a statistically significant amount, and we only have the margins of errors listed in the abstract to base this on. As we’ve said, exactly how they may have been calculated is unclear. Another issue is that the study doesn’t actually measure the risk of heart attacks directly, but the PULS score. There is little evidence on why this might be a reliable metric to measure the risk of heart attacks. Oncologist Dr David Gorski, notes that on the PULS test website, the evidence given for the claim that the test has been validated actually links to a paper which claims a different, though similar, biomarker test has been validated. Circulation also says of the research paper that “the author is not clear that only anecdotal data was used,” which means there may be an element of selection bias, affecting the legitimacy results. Additionally, the research has not been peer-reviewed. All these issues means the work cannot be used as a basis upon which to build the argument that Covid-19 vaccines increase the risk of heart attacks, as Dr Malhotra went on to say on GB News. Other evidence The Medicines and Healthcare products Regulatory Agency has identified an increased, though still low, risk of heart inflammation among young men in particular after receiving an mRNA vaccine. It has also noted that a side effect of the vaccines is a rapid heartbeat. It has not warned of any other link between the vaccines and any other heart condition. People who experience adverse health events after vaccination can report them via the Yellow Card scheme to be investigated.
  7. Germany will ban un-jabbed citizens from most public places, Merkel said today Non-essential retail, along with all leisure and cultural facilities, will be open only to those who have had their shots or have recovered from Covid Merkel also said parliament will begin debating whether to make jabs mandatory She then backed the move, saying: 'If I was in the Bundestag, I would vote for it' Germany will lock down its unvaccinated citizens while parliament debates making jabs mandatory, Angela Merkel said as she threw her weight behind the move today. The outgoing Chancellor said that un-jabbed people will soon be barred from non-essential shops and all cultural and leisure facilities, with only those who have got their shots or been infected with Covid allowed to enter. The Bundestag will also begin debating a vaccine mandate as soon as possible with a view to making it law by February next year, Merkel added. That would take Germany in line with Austria, which brings in mandatory vaccinations from February. Greece is also making jabs compulsory for over-60s. Speaking alongside incoming Chancellor Olaf Scholz who has also signalled his support for the move, she said: 'If I were in the Bundestag, I would vote for it. 'We all hoped that volunteering would be better accepted. [But] there is a vaccination gap that means... the health system is coming to the brink of overload.' Other lockdown measures include limiting both public and private gatherings attended by the unvaccinated to a maximum of four people from two households. Nightclubs will also be close in high-infection areas, schoolchildren will be forced to wear masks, and outdoor sporting events will be limited to a maximum of 50 per cent capacity. The sale of fireworks for New Year's Eve will be banned with the intention of discouraging crowds to gather, Merkel added. It was not immediately clear when the measures will take place, though Merkel referred to an 'Advent Lockdown' during her press conference - suggesting they will initially run up to Christmas. Health Minister Jens Spahn, in a caretaker role ahead of the planned swearing in of a new government next week, told the ZDF broadcaster earlier in the day that Germany needed 'a lockdown, so to speak, for the unvaccinated'. Infections have smashed German records in recent weeks and hospitals are sounding the alarm, with many over capacity and forced to dispatch patients elsewhere in the country for treatment. Though Germany's seven-day incidence rate has fallen slightly this week, it still stood at 439.2 on Thursday, with 73,209 new cases recorded in the past 24 hours. 'From the point of view of intensive and emergency medicine, the pandemic situation has never been as threatening and serious as it is today,' the DIVI intensive care association warned on Wednesday, calling for a drastic tightening of the rules. Several hard-hit German regions have already cancelled Christmas markets and barred the unvaccinated from public spaces like gyms and leisure facilities to slow the pandemic spread. About 69 per cent of the German population is currently fully vaccinated. That is below the theoretical 'herd immunity' limit of 70 per cent, and far below the minimum of 75 per cent the government has set at its target. Finance Minister Olaf Scholz, who is expected to be elected chancellor by a center-left coalition next week, said Tuesday that he backs a general vaccine mandate. But he added that he favors letting lawmakers vote according to their personal conscience rather than party lines on the matter. The rise in COVID-19 cases over the past several weeks and the arrival of the new omicron variant have prompted warnings from scientists and doctors that medical services in the country could become overstretched in the coming weeks unless drastic action is taken. Some hospitals in the south and east of the country have already transferred patients to other parts of Germany because of a shortage of intensive care beds. Agreeing what measures to take has been complicated by Germany's political structure - with the 16 states responsible for many of the regulations - and the ongoing transition at the federal level. Germany's disease control agency reported 73,209 newly confirmed cases Thursday. The Robert Koch Institute also reported 388 new deaths from COVID-19, taking the total since the start of the pandemic to 102,178. Germany already announced plans earlier this month to require health workers and soldiers to get inoculated against Covid-19. Expanding that to the general public would see the country follow the example of neighbouring Austria, which is planning mandatory vaccinations from February. Greece has announced mandatory jabs for over 60s, with unvaccinated people facing fines if they don't comply. EU chief Ursula von der Leyen said Wednesday it was time for the bloc to 'think about mandatory vaccination' against Covid, though she also stressed it was up to individual states to make the decision. 'My personal position is... I think it is understandable and appropriate to lead this discussion now,' she said.
  8. A 'fit and healthy' mother-of-two died from a blood clot 'likely' to have been caused by the AstraZeneca Covid-19 vaccine, an inquest has heard. Michelle Barlow, 51, began suffering headaches and nausea about a week after receiving her first dose of the jab in March. She was eventually admitted to hospital and then tragically died later that month. Senior coroner Timothy Brennand heard that Mrs Barlow, who worked as a civil servant for the Department of Work and Pensions for 34 years, had suffered blood clots likely to have been caused by the vaccine. An inquest at Bolton Coroners Court heard the condition was a 'very rare' side-effect to the AstraZeneca vaccine. Michelle, a mother-of two from Orrell in Wigan, received her first dose of the vaccine on March 7. Michelle's husband, Ian, told the hearing that in the days that followed, she began to experience 'flu-like symptoms', and later developed headaches, diarrhoea and nausea. By March 19, Mrs Barlow's symptoms had become 'overwhelming' so she sought help at Wigan Infirmary. Doctors carried out tests, which showed she had a 'very low' blood platelet count. She was discharged and told to return for a check-up the following week. However, Mrs Barlow's condition failed to improve and she was readmitted to hospital the next day. Doctors suspected she had a gastroenteritis infection, the inquest heard. Mr Barlow said the family was unable to be with her at the hospital due to Covid restrictions and on March 22 he got a phone call from a nurse telling him to get to the hospital as soon as possible. 'I knew something wasn't right,' he said. 'When I got that phone call, I expected to go and see my wife and she would survive.'
  9. Vaccine acts like a magnet and attracts platelets which body mistakes for a threat and attacks A new study has found possible link to rare jab blood-clots which has been connected to the death 73 Britons Scientists found the virus used in the jab attracts a protein in the blood, called platelet factor 4, like a magnet In a case of 'mistaken identity' the body's immune system then attacks this cluster, triggering the blood clots. Scientists believe they have solved the mystery behind the extremely rare blood clots caused by the Oxford-AstraZeneca vaccine. A team of international experts, involving researchers from AstraZeneca, say that in a very small number of cases — about one in 100,000 in the UK — the vaccine can set off a chain reaction which leads to the body confusing its own blood platelets for fragments of virus. The British-made vaccine is thought to have saved about a million lives from Covid and was the backbone of the UK's initial rollout earlier in the year, helping it to become the most vaccinated country in the West. But concerns about clots saw its restriction in under-40s in the UK in spring and led Pfizer and Moderna's vaccines being favoured for young adults and as boosters. It was outright banned in many European countries and the US decided not to purchase a single dose. The UK Government gave an emergency grant to a team of scientists led by Cardiff University to investigate the clotting phenomenon. They found that the shell of the vector vaccine — the weakened cold virus used to teach cells how to neutralise Covid — sometimes acts like a magnet and attracts platelets, a protein found in the blood. For reasons the scientists are still probing, the body then mistakes these platelets as a threat and produces antibodies to fight them. The combination of the platelets and the antibodies clumping together leads to the formation of dangerous blood clots. But they stress this is extremely rare, with only 426 cases in the UK recorded the cases so far out of about 50million doses of the vaccine, equivalent to less than one in 100,000. The side effect has been linked to 73 deaths in the UK. Researchers are now doing further work to learn more about the process that causes these clots and if the vaccine can be tweaked to reduce this risk. +3 In a very small number of cases — about one in 100,000 in the UK — the vaccine can set off a chain reaction which leads to the body confusing its own blood platelets for fragments of virus. The shell of the vector vaccine — the weakened cold virus used to teach cells how to neutralise Covid — sometimes acts like a magnet and attracts platelets, a protein found in the blood. For reasons the scientists are still probing, the body then mistakes these clumps as a threat and produces antibodies to fight them. The combination of the platelets and the antibodies clumping together leads to the formation of dangerous blood clots +3 +3 The left image shows a cloud of platelet factor 4 being pulled towards the surface of the adenovirus delivery system of the Oxford-AstraZeneca vaccine. Scientists suspect this is the start of a rare chain-reaction that could trigger life threatening blood clots. On the right is a detailed image of the adenovirus used in the Oxford-AstraZeneca jab to deliver a snippet of the Covid virus to prepare the human body's immune system for a possible infection The Oxford University-AstraZeneca jab is a adenovirus vaccine, meaning it contains a genetically altered virus, in this case chimpanzee cold virus, modified to be incapable of infecting the human body. The vaccine works by using the chimpanzee cold virus to deliver a portion of the Covid virus's genetic code which the body then learns to recognise and prepare itself for a real infection from the virus. Adenovirus technology is also used in the single dose Johnson and Johnson Covid vaccine which as also been linked to a small number of life threatening blood clot cases. The UK has donated the 20million doses of the Johnson and Johnson it ordered to the COVAX scheme — the UN's vaccine sharing programme. While the AstraZeneca jab has been proven to have saved thousands of lives, the rollout was marred after it was revealed there was a rare chance of developing a life threatening blood-clot after it was administered and deaths were reported. The fallout out led to the jab being restricted to the over 40s in the UK and banned entirely in some countries, although it was later revealed the risk of developing a similar life threatening blood clot from Covid itself was higher. Now the scientists involved in the new study, who published their findings in the Science Advances, say they may have uncovered the trigger causing theses rare vaccine triggered blood clots. Essentially, after being delivered into the body adenovirus binds with a specific protein in the blood, known as platelet factor 4 (PF4), which is normally used by the body to promote coagulation in case of injury. Using incredibly detailed images of the adenovirus in the vaccine the scientists demonstrated the adenovirus in the Oxford-AstraZeneca is negatively charged, and could attract positively charged proteins like a magnet. The researchers believe that in a case of 'mistaken identity' the body's immune system considers this platelet cluster as threat and releases antibodies to attack it, clumping together to it and triggering potentially life threatening blood clots. This condition is called vaccine-induced immune thrombotic thrombocytopenia (VITT). Professor Alan Parker, an expert in using adenoviruses in medicine from Cardiff University, and who was involved in the study, said: 'VITT only happens in extremely rare cases because a chain of complex events needs to take place to trigger this ultra-rare side effect. 'Our data confirms PF4 can bind to adenoviruses, an important step in unravelling the mechanism underlying VITT. Establishing a mechanism could help to prevent and treat this disorder.' Professor Parker said the team hopes their findings can be used to both better understand the rare side affects of the new Covid vaccines and design better jabs in the future. Researchers from Arizona State University were also involved in the study and used electro-microscope equipment to take incredible detailed images of the adenovirus used in the Oxford-AstraZeneca vaccine. A spokeswoman for the company told the BBC: 'Although the research is not definitive, it offers interesting insights and AstraZeneca is exploring ways to leverage these findings as part of our efforts to remove this extremely rare side effect.' Other Covid vaccine that use the adenovirus technology include the Johnson and Johnson single dose jab. The Medicines and Healthcare products Regulatory Agency, which body that examines safety of vaccines in the UK has identified 425 cases of major blood clots in Britons who have had the Oxford-AstraZeneca jab. A total of 73 of these were fatal. Of the 425 cases, 215 in women and 206 in men, 154 cases related to blood clots in the head and 271 in other parts of the body. Such blood clots are extremely rare however, with nearly 25 million people having received one dose and 24 million having received their second jab. Studies have showed the benefits of giving AstraZeneca's vaccine to 40-49 year-olds outweighed the potential risks, with the jab preventing 1.7 ICU admissions per 100,000 people, compared to the risk of 1.2 blood clots per 100,000 people. However this risk/benefit calculation swung the other way when it came to younger age groups. The AstraZeneca jab was pivotal to the UK's initial vaccine rollout in the closing weeks of 2020, helping it become the most vaccinated nation in the West at the time. Last week AstraZeneca boss Pascal Soriot suggested the UK's widespread adoption of the jab, compared to EU nations, could explain why the continent is starting to record higher intensive care rates despite having similar case numbers to Britain. Mr Soriot told the BBC Radio 4's Today programme: 'When you look at the UK there was a big peak of infections but not so many hospitalisations relative to Europe. In the UK this vaccine was used to vaccinate older people whereas in Europe initially people thought the vaccine doesn't work in older people. 'T-cells do matter…it matters to the durability of the response especially in older people, and this vaccine has been shown to stimulate T-cells to a higher degree in older people. 'We haven't seen many hospitalisations in the UK, a lot of infections for sure…but what matters is are you severely ill or not.' What is the risk of getting blood clot after AstraZeneca's jab? Earlier this year, British health chiefs recommended all under-40s are offered an alternative to AstraZeneca's vaccine because of blood clot fears. According to the Medicines and Healthcare products Regulatory Agency, as of September 1 there have been 425 cases of VITT and 73 deaths. But statisticians analysed the numbers and found rates were slightly higher among younger adults, with females appearing to be at most risk, too. Cambridge academics estimated around 1.9 in every 100,000 twenty-somethings given AstraZeneca's jab would suffer serious blood clots alongside abnormally low platelet levels (thrombocytopenia) — the specific disorder linked to the jab. For thirty-somethings the figure was 1.5. They compared that against the average number of Covid intensive care admissions that would be prevented by giving that cohort the jab. And they then analysed the risk/benefit ratio in different scenarios, based entirely on how widespread the disease was at the time. For example, only 0.2 ICU admissions would be prevented for every 100,000 twenty-somethings given the jab at prevalence levels seen in April (fewer than 30,000 infections per week). For adults in their thirties, the figure was around 0.8. It showed, however, the benefits of giving AstraZeneca's vaccine to 40-49 year olds outweighed the potential risk (1.7 prevented ICU admissions per 100,000 people compared to 1.2 blood clots). But the decision to recommend under-40s are offered Pfizer or Moderna's jab instead was basically only taken because the outbreak was squashed to extremely low levels, as well as the fact younger people are known to face tiny odds of falling seriously ill with coronavirus. For older adults, who the disease poses a much greater threat to, the benefits of vaccination are clear, regulators insist. Jabs have already saved around 13,000 lives in England, top scientists believe. However, because there were so few blood clots, it made it impossible for No10's vaccine advisory panel to give an exact age cut-off. Instead, they were only able to analyse figures by decade. The first clots to alarm people were ones appearing in veins near the brains of younger adults in a condition called CSVT (cerebral sinus venous thrombosis). Since that, however, people have developed clots in other parts of their bodies and they are usually linked to low numbers of platelets, which is unusual because platelets are usually used by the immune system to build the clots. In most cases people recover fully and the blockages are generally easy to treat if spotted early, but they can trigger strokes or heart or lung problems if unnoticed. Symptoms depend entirely on where the clot is, with brain blockages causing excruciating headaches. Clots in major arteries in the abdomen can cause persistent stomach pain, and ones in the leg can cause swelling of the limbs. Researchers in Germany believe the problem lies in the adenovirus vector — a common cold virus used so both vaccines can enter the body. Academics investigating the issue say the complication is 'completely absent' in mRNA vaccines like Pfizer's and Moderna's because they have a different delivery mechanism. Experts at Goethe-University of Frankfurt and Ulm University, in Helmholtz, say the AstraZeneca vaccine enters the nucleus of the cell – a blob of DNA in the middle. For comparison, the Pfizer jab enters the fluid around it that acts as a protein factory. Bits of coronavirus proteins that get inside the nucleus can break up and the unusual fragments then get expelled out into the bloodstream, where they can trigger clotting in a tiny number of people, scientists claim.
  10. Yep your so right Fresh of the press today!!!!!!!! AstraZeneca uncovers what's triggering blood clots after its jab: Vaccine acts like a magnet and attracts platelets which body mistakes for a threat and attacks A new study has found possible link to rare jab blood-clots which has been connected to the death 73 Britons Scientists found the virus used in the jab attracts a protein in the blood, called platelet factor 4, like a magnet In a case of 'mistaken identity' the body's immune system then attacks this cluster, triggering the blood clots
  11. DrDecorator, if you look closely you will see staff standing talking and taking pictures with no mask on in a very busy cramped place, what do you think, are they following the Rules
×
×
  • Create New...